Table 1.
Baseline characteristics
| Total cohort | Klotho <460 pg/mL | Klotho >460 pg/mL | |
|---|---|---|---|
| n = 127 | n = 63 | n = 64 | |
| Age, years | 67 ± 7 | 67 ± 7 | 67 ± 8 |
| Gender, female | 30 (24%) | 10 (16%) | 20 (31%)* |
| Pulse pressure, mmHg | 59 ± 24 | 59 ± 24 | 59 ± 16 |
| Hypertension | 104 (82%) | 53 (87%) | 51 (80%) |
| Diabetes | 43 (34%) | 24 (40%) | 19 (30%) |
| Dialysis Modality, PD | 42 (33%) | 8 (13%) | 34 (53%)*** |
| Dialysis vintage, years | 2.3 ± 2 | 2.6 ± 2.7 | 2.0 ± 2.2 |
| RRF, (ml/min/1.73 m2) | 1.8 ± 1.6 | 1.7 ± 1.8 | 2.0 ± 1.4 |
| Anuria | 30 (24%) | 20 (33%) | 10 (16%)* |
| Phosphate (mmol/L) | 1.5 ± 0.4 | 1.6 ± 0.4 | 1.5 ± 0.4 |
| Calcium (mmol/L) | 2.4 ± 0.2 | 2.4 ± 0.2 | 2.4 ± 0.2 |
| FGF-23 (RefU/mL) | 7247 ± 16815 | 8723 ± 21627 | 5794 ± 10044 |
| 25(OH)D (nmol/L) | 87 ± 57 | 102 ± 65 | 71 ± 42** |
| PTH (pmol/L) | 35 ± 34 | 42 ± 41 | 28 ± 22* |
| Creatinine (umol/L) | 659 ± 202 | 642 ± 211 | 676 ± 195 |
| CRP (mg/L) | 14.3 ± 30.7 | 20.1 ± 41.7 | 8.9 ± 12.22* |
| β -blocker | 71 (56%) | 37 (60%) | 34 (54%) |
| ACEi | 32 (25%) | 19 (31%) | 13 (21%) |
| ARB | 37 (29%) | 13 (21%) | 24 (38%)* |
| Statin | 79 (62%) | 43 (69%) | 36 (57%) |
| NCPB | 107 (84%) | 54 (87%) | 53 (84%) |
| CCPB | 50 (39%) | 25 (40%) | 25 (40%) |
| Cinacalcet | 15 (12%) | 7 (12%) | 8 (13%) |
PD; Peritoneal dialysis, RRF; Residual Renal Function, FGF-23; Fibroblast Growth Factor 23. PTH; Parathyroid hormone, ACEí; Angiotensin Converting Enzyme inhibitor, ARB; Angiotensin receptor blocker, NCPB; Non calcium containing phosphate binder, CCPB; Calcium containing phosphate binder. *;p < 0.05, **;p < 0.01; ***;p < 0.001.